Human Papillomavirus (HPV) Vaccine Background Paper.
New evidence published today in the Cochrane Library shows that human papilloma virus (HPV) vaccines protect against cervical lesions in young women, particularly in those who are vaccinated between the ages of 15 and 26. It also summarizes findings on harms that have been assessed in randomized controlled trials. Below is a Science Media Centre roundup of third-party expert reaction to this.
The research shows the HPV vaccine is efficacious in reducing cervical pre-cancers among young women throughout a population. Cosette Wheeler, PhD, at The University of New Mexico Comprehensive Cancer Center, led the research team and the efforts of the New Mexico Human Papillomavirus Pap Registry, the data source used in the study.
Parents’ favorable beliefs about the HPV vaccine is a key factor for acceptance of the vaccine, as discussed in previous research in different contexts (10, 20, 26, 27, 56). Background knowledge of the HPV vaccine was positively related to acceptance, indicating the importance of parents having knowledge about the vaccine before implementation.
More recently, two HPV vaccines, Cervarix and Gardasil, became available in the market. These vaccines target HPV types that most commonly cause cervical cancer. The bivalent vaccine (Cervarix) and quadrivalent vaccine (Gardasil) can protect against HPV types 16 and 18, which worldwide are responsible for about 70% of cervical cancer.
Human papillomavirus (HPV) vaccines are vaccines that prevent infection by certain types of human papillomavirus. Available vaccines protect against either two, four, or nine types of HPV. All vaccines protect against at least HPV types 16 and 18, which cause the greatest risk of cervical cancer. It is estimated that the vaccines may prevent 70% of cervical cancer, 80% of anal cancer, 60% of.
Clinical trials of Gardasil involving more than 4,000 males aged 16 to 26 years from 18 countries showed the vaccine was 90% effective against HPV types 6, 11, 16 and 18 that cause genital warts and penile lesions, and 78% effective against HPV types 6, 11, 16 and 18 that cause anal lesions in men.
Background: School nurses play important roles in delivering human papillomavirus (HPV) vaccination programme in United Kingdom. International research indicates lower HPV vaccination uptake rates among Black, Asian and Minority Ethnic (BAME) groups (Fisher et al. 2013) and suggests socio-cultural factors influence vaccine refusal (Boyce and Holmes 2013).